Although the effect of this SNP of CD39 on phenotypic change remains unknown, several authors have suggested CD39 could be a checkpoint inhibitor target in that it prevents adenosine’s immunosuppressive effects, thus playing an important role in tumour progression [33]. This evidence concerns the gene ENTPD1 and neoplasm.